Bioporto A/S
CSE:BIOPOR
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.222
2.965
|
Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bioporto A/S
Free Cash Flow
Bioporto A/S
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Bioporto A/S
CSE:BIOPOR
|
Free Cash Flow
-kr56m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-13%
|
||
Genmab A/S
CSE:GMAB
|
Free Cash Flow
kr6.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
53%
|
CAGR 10-Years
N/A
|
||
Zealand Pharma A/S
CSE:ZEAL
|
Free Cash Flow
-kr711.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-29%
|
||
Ascendis Pharma A/S
NASDAQ:ASND
|
Free Cash Flow
-€262.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-33%
|
||
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Free Cash Flow
kr882.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
F
|
Fluoguide AS
STO:FLUO
|
Free Cash Flow
-kr31.8m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-667%
|
CAGR 10-Years
N/A
|
Bioporto A/S
Glance View
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
See Also
What is Bioporto A/S's Free Cash Flow?
Free Cash Flow
-56m
DKK
Based on the financial report for Jun 30, 2024, Bioporto A/S's Free Cash Flow amounts to -56m DKK.
What is Bioporto A/S's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-13%
Over the last year, the Free Cash Flow growth was 11%. The average annual Free Cash Flow growth rates for Bioporto A/S have been -5% over the past three years , -4% over the past five years , and -13% over the past ten years .